Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer

详细信息    查看全文

• 作者：Krushna?C. Patra ; Qi Wang ; Prashanth?T. Bhaskar ; Luke Miller ; Zebin Wang ; Will Wheaton ; Navdeep Ch ; el ; Markku Laakso ; William?J. Muller ; Eric?L. Allen ; Abhishek?K. Jha ; Gromoslaw?A. Smolen ; Michelle?F. Clasquin ; R.?Brooks Robey ; Nissim Hay
• 刊名：Cancer Cell
• 出版年：2013
• 出版时间：12 August, 2013
• 年：2013
• 卷：24
• 期：2
• 页码：213-228
• 全文大小：3842 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Accelerated glucose metabolism is a common feature of cancer cells. Hexokinases catalyze the first committed step of glucose metabolism. Hexokinase 2 (HK2) is expressed at high level in cancer cells, but only in a limited number of normal adult tissues. Using Hk2 conditional knockout mice, we showed that HK2 is required for tumor initiation and maintenance in mouse models of KRas-driven lung cancer, and ErbB2-driven breast cancer, despite continued HK1 expression. Similarly, HK2 ablation inhibits the neoplastic phenotype of human lung and breast cancer cells in?vitro and in?vivo. Systemic Hk2 deletion is therapeutic in mice bearing lung tumors without adverse physiological consequences. Hk2 deletion in lung cancer cells suppressed glucose-derived ribonucleotides and impaired glutamine-derived carbon utilization in anaplerosis.